Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSION tenecteplase for acute ischemic stroke in patients taking direct oral anticoagulants
2025-521762-99-00Phase 3Authorised
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Tenecteplase with Placebo (2 arms). Primary endpoint: Functional outcome at 90 days. Planned start Mar 2026; status: authorised.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-521762-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521762-99-00.